SLC22A12 and hyperuricemia: These distinct binding modes of benzbromarone and dotinurad within the URAT1 active site not only explain their different potencies but also provide valuable structural insights for the rational design and optimization of next-generation URAT1-targeted therapeutics for managing hyperuricemia and gout.